The Eastern Cooperative Oncology Group (ECOG)-1609 (stage IIIB-IV melanoma) trial reported increased relapse-free survival (RFS) with adjuvant anti-CTLA-4 therapies versus high-dose interferon-based therapies (interferon-alfa-2b) [3]. Here, CTLA4 is linked to melanoma.